Oxford Immunotec

Oxford Immunotec is a world-leading diagnostics company focused on providing single-visit blood tests for tuberculosis, one of the most common infectious diseases which kills over 1.5 million people a year in developed and emerging markets alike¹. Quick and accurate testing is crucial to identifying the disease and allowing timely, life-saving treatment. However, many latent infections can go unnoticed and develop in tuberculosis at a later stage, causing complications particularly among the immuno-compromised.

Venture capital investment enabled Abingdon, UK-based Oxford Immunotec to spin out of Oxford University to develop its innovative T-SPOT.TB test. The T-cell technology-based test, which is able to pick up infections that traditional skin testing can miss, is now approved in over 50 countries around the world, with over 20 million tests manufactured to date. The company went public on the Nasdaq in 2013² and was bought by global diagnostics specialist PerkinElmer in 2021 for $591 million³.